Skip to content
Company Analysis

Exagen Inc. XGN

A comprehensive view of key metrics, scores, and financial health for Exagen Inc.

Overview of Exagen Inc.

XGN NGM
Healthcare Diagnostics & Research Framework: Medical Devices & Diagnostics Micro Cap
Exagen Inc. (XGN), is a Micro Cap company, in the Diagnostics & Research industry, last closed at $7.30, about 59.3% overvalued vs fair value, -25.1% 1Y return, ranked 922/1145 in sector.
Metrics Rev Growth 19.7% ROE -147.9% Gross Margin 58.3%
USD 7.30
-3.69%
(Delayed)
• Vol 90d: 104.7%
52-Week Range
Market Cap
$111.62M
Enterprise Value
$113.07M
Overall Score
View breakdown
Overall
Growth
Weak
Profitability
Fair
Health
Fair
Efficiency
Weak
Valuation
Weak
Growth
Weak
Profitability
Fair
Health
Fair
Efficiency
Weak
Valuation
Weak
Completeness: 100%
Confidence: 60%
Updated: Sep 12
Top Beats
No strong beats yet

Quick Facts

Website https://www.exagen.com
HQ Vista, CA
Employees 209
Fiscal year Dec 31

Next Events

No upcoming events available.

Fair Value Snapshot

Bear Base Bull
$2
$3
$4
Current: $7.30 -59% vs base

Engine Room Money Flow™

Micro Cap

Medical Devices & Diagnostics - Where revenue goes and how value is created

Flow Steps
Total Revenue
$66.6M
19.7%%
Gross Profit
$38.8M
17.2%%
Operating Income (GAAP)
$-14.1M
-3.2%%
EBITDA
$-13.5M
-20.8%%
Money Flow Bridge
Flow Direction: Money moves from left to right
Components: Breakdown shows composition of each stage
Industry-Specific: Medical Devices & Diagnostics

Quality & Reliability Indicators

Gross Margin
58.3%
Good

Gross Profit / Revenue — primary moat signal for MedTech. ≥65% indicates IP-protected consumables with strong pricing power.

Locked Metric
-
Premium
Locked Metric
-
Premium
Locked Metric
-
Premium
Locked Metric
-
Premium
Locked Metric
-
Premium
Locked Metric
-
Premium

Where It Leaks

Cash Flow Health critical
Significant cash flow inefficiencies identified. Multiple high-impact leaks require attention.
2
Active Leaks
1/2
Improving
0
High Impact
2
Critical
Locked Leak
Upgrade to view details
Premium
Moat Analysis Medical Devices & Diagnostics

Competitive Advantage Assessment

Evaluating Exagen Inc.'s durable competitive advantages across 6 defense dimensions

Overall Moat Strength
45
/100
Developing
Scores based on quantitative metrics and qualitative factors
Full moat analysis

Key strengths

  • Expanding Operating Margin Operating margin trend is positive (score 0.65). Margin expansion confirms commercial leverage is building.
  • Durable Revenue Growth Revenue growth trend is strong (score 0.83). Durable top-line expansion confirms the razor-and-blade flywheel is working.

Key risks

  • Weak Capital Return Profile Capital return quality is below peers (score 0.23). Low ROIC raises questions about M&A discipline and pipeline ROI.
  • Weak FCF Generation FCF margin quality lags peers (score 0.33). Below-peer FCF conversion is a MedTech quality warning.

The dashed ring is the peer median. Defense scores are percentile ranks against peers, so 50 is roughly the typical company in this group.

Upgrade to unlock the signals and evidence behind each defense.

Premium access

Unlock full defense analysis

Get key signals, strengths, and risks for every moat dimension.

Upgrade to Premium Unlock all moat defenses and evidence.

Pricing Power & Consumable Moat

Moderate
56
Premium
Unlock full defense details

See key signals plus strengths and risks for this moat dimension.

Upgrade for full defense analysis Premium-only evidence and insights.
For informational purposes only. Not investment advice.
Premium
Unlock full defense details

See key signals plus strengths and risks for this moat dimension.

Upgrade for full defense analysis Premium-only evidence and insights.
For informational purposes only. Not investment advice.
Premium
Unlock full defense details

See key signals plus strengths and risks for this moat dimension.

Upgrade for full defense analysis Premium-only evidence and insights.
For informational purposes only. Not investment advice.
Premium
Unlock full defense details

See key signals plus strengths and risks for this moat dimension.

Upgrade for full defense analysis Premium-only evidence and insights.
For informational purposes only. Not investment advice.
Premium
Unlock full defense details

See key signals plus strengths and risks for this moat dimension.

Upgrade for full defense analysis Premium-only evidence and insights.
For informational purposes only. Not investment advice.
Premium
Unlock full defense details

See key signals plus strengths and risks for this moat dimension.

Upgrade for full defense analysis Premium-only evidence and insights.
For informational purposes only. Not investment advice.

Trade-Off Ledger™

Where management spends the performance budget - Growth, Profitability, or Safety

Generic Industrial / Default vs Industry Peers 88% Coverage
Trade-Off Triangle Visualization A ternary plot showing XGN's balance between Growth (38.3%), Profitability (26.8%), and Safety (34.9%). Growth 38% Safety 35% Profitability 27%

Click axes to expand details. Marker shows current allocation.

3-Year Trend Analysis Locked
Upgrade to unlock the full 3-year trend analysis and deltas.

Growth

59th percentile vs peers
59
Key Signals
Rev Growth YoY 19.7% 76p Revenue CAGR 3Y 13.5% 64p EPS Growth YoY -11.5% 26p
Strengths
  • Strong liquidity position vs peers
Risks

No significant risks identified for this axis.

Profitability

41th percentile vs peers
41
Key Signals
Strengths
Risks
Premium
Unlock full Profitability drilldowns

See the signal-level drivers and insights behind this axis. Upgrade to reveal the full Trade-Off Ledger.

Upgrade Now

Safety

53th percentile vs peers
54
Key Signals
Strengths
Safety drilldowns are available to premium members.

Two Futures

Scenario-based fair value ranges for Exagen Inc..

Loading valuation model...
Unable to Compute Fair Value

This company cannot be valued using standard models.

What this means: The Scenario Theatre requires financial data (revenue, cash flow, shares outstanding) to calculate fair value estimates. This data may be unavailable for:

  • Recently listed companies (IPOs, SPACs)
  • Shell companies or holding companies
  • Companies that haven't filed recent financials
  • Foreign companies with limited data coverage
X.X%
X%XX%
X.X%
-XX%XX%
XX.X%
-XX%XX%
Adjust the sliders above to explore different valuation scenarios.
Unlock Premium
Reveal the full Scenario Theatre
See live sliders, narratives, and full Bear/Base/Bull outcomes.
Upgrade Now
Bear
-
- - -
- upside
-
Base
$2.97
- - -
-59.3% vs current
Snapshot base estimate
Bull
-
- - -
- upside
-
Fair Value Range Current: $-
$- $- $-
Actions & Info
Send Feedback
Please select a category.
0/1000